Predictive biomarkers for tumor immune checkpoint blockade
Open Access
- 1 October 2018
- journal article
- review article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 10, 4501-4507
Abstract
The development of immune checkpoint inhibitors represented by PD-1 and PD-L1 has provided new hope for the treatment of advanced cancer patients. However, there are no effective predictive biomarkers, which have caused many limitations to the clinical application of immune checkpoint inhibitors. This paper combines recent domestic and international research as well as clinical trials to discuss the current status and progress of PD-L1 expression as a biomarker for tumor immunotherapy and also to discuss whether tumor mutation burden, tumor-infiltrating lymphocytes, tumor cell gene expression profiling, or peripheral blood markers would be a potential predictive biomarker for novel tumor immunotherapy. So, a brief review on this hot topic of predictive biomarkers for tumor immunotherapy is conducted.Keywords
This publication has 54 references indexed in Scilit:
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory CheckpointsCancer Discovery, 2015
- Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: A preliminary studyOral Oncology, 2015
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic TumorsImmunity, 2014
- The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysisBreast Cancer Research and Treatment, 2014
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancerAnnals of Oncology, 2014
- Tumor-Infiltrating Lymphocytes and Their Significance in Melanoma Prognosis2013
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)Proceedings of the National Academy of Sciences, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)Cancer, 2007
- Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?Lung Cancer, 2004